Why BGPT?
logo

Tables Built From Reported Results

Assemble tables from exact reported values and versioned claims, with provenance back to every source paper.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Long Analysis Plan



    Model Sets Extracted From the EGFR-Focused Evidence Records

    StudyModel TypeModels / Systems UsedKey Numeric Outcomes
    LDOC1–clathrin adaptor control of EGFR internalization (IjMS 2024)Clinical cohort + cell lines200 advanced NSCLC patients (100 EGFR-mutant on gefitinib; 100 EGFR-WT on chemotherapy), follow-up 0.4–70.5 months; cell lines A549, PC9, HCC827, U2OSCytoplasmic EGFR: WT/high-LDOC1 9.1% vs WT/low 42.2%; mutant/high 12.1% vs mutant/low 59.5%. LDOC1-high/low: EGFR-WT 55/45, EGFR-mutant 58/42. HCC827 gefitinib IC50 rose 1.8β†’2.3 Β΅M with LDOC1 depletion; osimertinib IC50 unchanged (~0.9 Β΅M); low LDOC1 β†’ shorter OS (p < 0.001)
    pSTAT3 transactivation of EGFR (ABBS 2024)Cell lines onlyA549, H1975, PC-9, H1299, HEK 293TNo numeric IC50/outcome values reported in the extract; qualitative finding: reduced membrane EGFR enhances nuclear pSTAT3 β†’ EGFR transcription and TKI resistance
    EGFR GCN vs mutation status (Pathology 2014)Human tissue cohort96 resected lung adenocarcinomas (52 M / 44 F, median age 67, range 30–86)34/96 SISH-positive (35%); 31/96 EGFR-mutant (32%); low sensitivity/PPV β€” GCN not a useful mutation screen. Case-level examples: 8 of 10 tabulated mutants were SISH-negative
    FUT8–EGFR core fucosylation vs antiviral immunity (Nat Commun 2024)Cell lines + mouse modelsHuh7, Huh7.5.1, HEK293T, EGFR-KO, FUT8-KO lines (n=3 biological replicates); ICR 4R+ mice (Fut8 silencing, n=3/group); C57BL/6J + VSV + 2FF (n=3–4/group)FUT8 mRNA up 3–10-fold at 6–12 h post-HCV; EGFR N352Q abolishes endocytosis and pJAK1/pSTAT3; FUT8 overexpression raises HCV RNA/NS3; Fut8 silencing or 2FF lowers HCV/VSV replication and raises IFN-I/Ifnb1
    CIN85 phosphorylation in EGFR sorting (MBoC 2012)Cell linesHeLa, HuH7, SYF MEFs, 3T9 fibroblasts (β‰₯30 cells/condition quantified)CIN85-4F: ~80% reduced c-Cbl binding, ~70% reduced EGFR ubiquitination, >50% reduced MVB sorting (p<0.0001), early-endosome retention at 2 h (p<0.0005); WT EGFR ~90% degraded by 90 min vs ~50% retained with 4F; Src re-expression accelerates degradation 3–4-fold in SYF cells
    EGFR-TKI sensitivity by mutation (JTO 2017 abstract)Cell linesPC9 (ex19del), H3255 (L858R), H1975 (G719S+T790M; L861Q+T790M), BID007 (ex20ins), Ba/F3 mutantsH1975 double-mutant IC50 ~100 nM (osimertinib); PC9/H3255 IC50 lower than nazartinib; BID007 ex20ins sensitivity similar between osimertinib and nazartinib
    EGFR-targeted nanoparticles (J Control Release 2012)Cell line + xenograftA431 cells; female nude mice with A431 tumorsUp to 90% internalization of targeted Ni-NPs in A431 cells; ~2-fold higher intratumoral nickel vs untargeted NPs
    EGFR pathway review (Future Oncol 2011)Narrative reviewSynthesis of NSCLC literature; no new modelsNo new numeric outcomes; consolidates biomarker evidence (mutations predictive; GCN/protein expression inconsistent)

    Notes on comparability: Direct quantitative comparison is possible only for the IC50 and trafficking measurements above; several studies report qualitative or figure-only values (e.g., PC9 shLDOC1 gefitinib IC50 exact value not stated in text), and the 2017 TKI study reports approximate nM values for a single line only. These gaps limit pooled inference.

    Figure: only IC50 values explicitly reported in the extracts are plotted; the H1975 ~100 nM value is converted for scale. PC9 gefitinib/erlotinib IC50 increases with LDOC1 knockdown were reported qualitatively only and are therefore excluded.

    Figure: clinical IHC subgroup values from the 200-patient NSCLC cohort, showing the association of low LDOC1 with cytoplasmic (internalized) EGFR.



    Feedback:    

    Updated: October 25, 2026

     Top Data Sources ExportMCP



     Analysis Wizard



    Compiling a structured dataframe of cell-line models, mutations, and reported IC50/percentage outcomes from the EGFR studies to support cross-study comparison and meta-summary statistics.



     Science Art


    Create Tables: Extract all model sets and key numeric outcomes from Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT